Pharmaceutical Technology® spoke with Peter Belden, president of Tjoapack US, ahead of DCAT Week 2025 to discuss recent innovations in bio/pharmaceutical packaging.
The evolution of personalized medicine and their complexity, such as temperature-sensitive therapies and customized packaging configurations, is impacting the biopharmaceutical packaging market, according to Peter Belden, president of Tjoapack US. Pharmaceutical Technology® spoke to Belden ahead of DCAT Week 2025, which is being held March 17–20 in New York City, to get perspective on how recent innovations in biopharmaceutical manufacturing are impacting the pharma packaging market.
“We've been investing heavily in expanding our cold chain capabilities, in expanding our capability and capacity to package unique configuration for injectable products, whether that is a product that comes to us in a syringe format, a vial format, or an auto injector format,” Belden says. “[We have] the ability to either automate or semi-automate, label, and then finish [to] pack those products while maintaining tight control of time [and] temperature to allow for packaging, and then getting those materials and finished goods back into cold storage. [We also serve] as a potential logistics hub for several of our clients to manage the supply complexity, then shipping those time- and temperature-sensitive medicines to the many markets around the world that our client base is serving.”
Click the video above to watch the interview.
Peter Belden is president of Tjoapack US.
